The Hypo-RESOLVE consortium met for its 1st Annual Progress Meeting from May 08-10, 2019 in Nijmegen, The Netherlands, at the Radboud University Medical Centre (RUMC), Coordinator in this IMI2 JU public-private- partnership project. The Auditorium at RUMC provided the perfect setting for the meeting, and the hospitality and excellent preparation of the event allowed partners to completely focus on the comprehensive agenda.
The afternoon of the first day was reserved for internal work package meetings, bringing the members together face-to-face to discuss the current status and future activities. The Patient Advisory Committee hosted a session on how to engage with the various working groups and tasks.
The second day was dedicated to plenary sessions. After a warm welcome by the Project Coordinator, Dr Bastiaan de Galan from RUMC and the Project Leader, Dr Stephen Gough from Novo Nordisk (NN), who also conveyed the regards of the IMI Project Officer, the following sessions focused on relevant thematic clusters of the project. The clusters on “Data & Analysis”, “Putting Persons with Diabetes first”, “Clinical Trials” and “Making use of Future Results” were each introduced and moderated by a dedicated chairperson, followed by topic-related presentations and a Q&A and discussion session. The sessions showcased the tremendous progress made and provided a comprehensive overview of the achievements of Hypo-RESOLVE as well as the planned activities and also allowed for critical assessment and inspiring fruitful discussions. The agenda for that day ended with the General Assembly meeting, which was led by Project Leader Novo Nordisk and supported by Project Management Partner Eurice. It focused on consortium management update and introduced the newly established Ethics Register serving as a repository for documents related to the action’s Ethics requirements. Furthermore, the date and location of next year’s annual meeting was determined – it will take place in Wiesbaden, Germany, from 13 to 15 May 2019 and will be kindly hosted by partner Abbott. After the scientific part of the day came to an end, the consortium rounded the tightly-packed day off with a joined dinner and a lively quiz around Hypo-RESOLVE topics.
Day 3 started with the statements by Strategic Advisory Board member Prof Helen Murphy and Ethics Advisory Board members Prof Evert van Leeuwen and Prof Otto Boerman, enriching the meeting with their expertise and offering valuable advice to the consortium. Their respective statements were followed by two sets of breakout sessions, including “Clinical Trials” led by partner KCL and “Publication Committee and Communication Committee” led by Eurice, where partners had the opportunity to talk about and plan project activities for the coming months. The day ended with a synthesis of each breakout session by the chairs and a wrap-up of this successful event by the Coordinator and Project Leader.